A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients with other clinical manifestations of atherosclerotic cardiovascular ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

WEDNESDAY, April 2, 2025 (HealthDay News) -- For patients with symptomatic peripheral artery disease and type 2 diabetes, ...

A shocking new study reveals that a condition that can lead to limb amputation is far more prevalent and deadly than ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Discover why remnant cholesterol, not LDL, is key to peripheral artery disease. Learn implications for prevention.